Financial Ratios Myriad Genetics, Inc.
Equities
MYGN
US62855J1043
Medical Equipment, Supplies & Distribution
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.82 USD | +2.03% |
|
-0.54% | -6.20% |
Feb. 05 | Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay | MT |
Feb. 05 | Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay | RE |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 1.35 | -5.68 | -5.78 | -6.14 | -7.4 | |||||
Return on Total Capital | 1.6 | -6.65 | -7.1 | -7.4 | -8.83 | |||||
Return On Equity % | 0.43 | -19.89 | -2.94 | -12.08 | -31.55 | |||||
Return on Common Equity | 0.45 | -19.88 | -2.94 | -12.08 | -31.55 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 76.38 | 69.51 | 71.39 | 70.22 | 68.64 | |||||
SG&A Margin | 62.82 | 85.69 | 77.87 | 75.87 | 75.31 | |||||
EBITDA Margin % | 12.04 | -16.18 | -9.25 | -10.47 | -10.98 | |||||
EBITA Margin % | 10.43 | -17.85 | -11 | -12.18 | -12.76 | |||||
EBIT Margin % | 3.47 | -28.12 | -18.35 | -18.23 | -18.44 | |||||
Income From Continuing Operations Margin % | 0.52 | -17.71 | -3.94 | -16.51 | -34.96 | |||||
Net Income Margin % | 0.54 | -17.71 | -3.94 | -16.51 | -34.96 | |||||
Net Avail. For Common Margin % | 0.54 | -17.71 | -3.94 | -16.51 | -34.96 | |||||
Normalized Net Income Margin | 1.63 | -18.89 | -12.05 | -11.4 | -11.8 | |||||
Levered Free Cash Flow Margin | 7.02 | 17.15 | 21.79 | -17.06 | -8.16 | |||||
Unlevered Free Cash Flow Margin | 7.9 | 18.2 | 22.39 | -16.76 | -7.91 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.62 | 0.43 | 0.5 | 0.54 | 0.64 | |||||
Fixed Assets Turnover | 16.94 | 7.97 | 6.12 | 4.34 | 4.09 | |||||
Receivables Turnover (Average Receivables) | 7.29 | 6.32 | 7.64 | 7.03 | 6.98 | |||||
Inventory Turnover (Average Inventory) | 6.12 | 6.15 | 9.32 | 11.41 | 11.22 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.96 | 2.67 | 2.37 | 2 | 2.01 | |||||
Quick Ratio | 2.34 | 1.66 | 2.11 | 1.58 | 1.64 | |||||
Operating Cash Flow to Current Liabilities | 0.71 | -1.01 | 0.09 | -0.77 | -0.71 | |||||
Days Sales Outstanding (Average Receivables) | 50.05 | 57.89 | 47.78 | 51.89 | 52.31 | |||||
Days Outstanding Inventory (Average Inventory) | 59.65 | 59.49 | 39.16 | 31.98 | 32.53 | |||||
Average Days Payable Outstanding | 54.63 | 54.76 | 49.21 | 51.54 | 41.85 | |||||
Cash Conversion Cycle (Average Days) | 55.07 | 62.62 | 37.73 | 32.34 | 42.99 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 21.44 | 32.8 | 9.54 | 16.37 | 19.42 | |||||
Total Debt / Total Capital | 17.66 | 24.7 | 8.71 | 14.07 | 16.26 | |||||
LT Debt/Equity | 21.44 | 31.26 | 8.19 | 14.78 | 17.35 | |||||
Long-Term Debt / Total Capital | 17.66 | 23.54 | 7.48 | 12.7 | 14.53 | |||||
Total Liabilities / Total Assets | 30.32 | 37.91 | 26.72 | 26.1 | 31.69 | |||||
EBIT / Interest Expense | 2.46 | -14.53 | -19.2 | -38.66 | -47.9 | |||||
EBITDA / Interest Expense | 8.54 | -8.36 | -6.55 | -15.72 | -19.59 | |||||
(EBITDA - Capex) / Interest Expense | 7.82 | -9.72 |